Show simple item record

dc.contributor.authorKnutson, Keith L.en_US
dc.contributor.authorSchiffman, Kathyen_US
dc.contributor.authorDisis, Mary L.en_US
dc.date.accessioned2010-03-31T18:47:12Z
dc.date.available2010-03-31T18:47:12Z
dc.date.issued2001-02-15en_US
dc.identifier.citationKnutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001;107(4):477-484.en_US
dc.identifier.other10.1172/JCI11752en_US
dc.identifier.urihttp://www.jci.org/articles/view/11752en_US
dc.identifier.urihttp://hdl.handle.net/1773/15594
dc.description.abstractCD4 T-cell help is required during the generation and maintenance of effective antitumor CD8 T cell–mediated immunity. The goal of this study was to determine whether HER-2/neu–specific CD8 T-cell immunity could be elicited using HER-2/neu–derived MHC class II “helper” peptides, which contain encompassed HLA-A2–binding motifs. Nineteen HLA-A2 patients with HER-2/neu–overexpressing cancers received a vaccine preparation consisting of putative HER-2/neu helper peptides p369–384, p688–703, and p971–984. Contained within these sequences are the HLA-A2–binding motifs p369–377, p689–697, and p971–979. After vaccination, the mean peptide-specific T-cell precursor frequency to the HLA-A2 peptides increased in the majority of patients. In addition, the peptide-specific T cells were able to lyse tumors. The responses were long-lived and detectable for more than 1 year after the final vaccination in select patients. These results demonstrate that HER-2/neu MHC class II epitopes containing encompassed MHC class I epitopes are able to induce long-lasting HER-2–specific IFN-γ–producing CD8 T cells.en_US
dc.description.sponsorshipDepartment of Defense Breast Cancer Program (Knutson). NIH grants, the National Cancer Institute (R01 CA75163), and the Department of Defense Breast Cancer Program (Dsis). NIH grant MO1-RR-00037.en_US
dc.language.isoen_USen_US
dc.titleImmunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record